Condition: Hepatocellular Carcinoma · Sponsor: Humanity & Health Medical Group Limited
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
This description comes directly from the study's public registry record.
Danny Wang, PhD · +852-21160598 · danny.wang@hnhmgl.com
Always discuss trial participation with your own doctor first.
| Beijing 302 Hospital | Beijing, China | Recruiting |
| Humanity & Health Medical Group Limited | Hong Kong, Hong Kong | Recruiting |
| Tokyo University | Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03612726